Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries and NATCO Pharma Limited, announced the launch of additional strengths for the generic version of Revlimid® (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S.
The companies have launched four other strengths of the product in March 2022 in the U.S. market. The companies have now made all strength of lenalidomide available in the U.S. market. Teva’s lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment.